Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.

ABSTRACT: Accumulating clinical evidence suggests that adoptive T-cell immunotherapy could be a promising option for control of cancer; evident examples include the graft-vs-leukemia effect mediated by donor lymphocyte infusion (DLI) and therapeutic infusion of ex vivo-expanded tumor-infiltrating lymphocytes (TIL) for melanoma. Currently, along with advances in synthetic immunology, gene-modified T cells retargeted to defined tumor antigens have been introduced as "cellular drugs". As the functional properties of the adoptive immune response mediated by T lymphocytes are decisively regulated by their T-cell receptors (TCRs), transfer of genes encoding target antigen-specific receptors should enable polyclonal T cells to be uniformly redirected toward cancer cells. Clinically, anticancer adoptive imm

SUBMITTER: Fujiwara H 

PROVIDER: S-EPMC4276906 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature